WhichPeps

NAD+

Endogenous dinucleotide coenzyme, not a peptide

Cellular metabolismageing and IV wellness…
Generic peptide vial illustrationNAD+
Evidence levelHuman evidence
Human evidenceHuman exposure
Regulatory statusNo broad wellness/ageing approval

What you need to know in 20 seconds

What is it?Endogenous dinucleotide coenzyme, not a peptide
Research focusCellular metabolism, ageing and IV wellness research
Human evidenceDirect IV NAD+ human evidence remains sparse. Small infusion studies characterize metabolism/tolerability, while a 2026 systematic review found no eligible IV/IM NAD+ outcome trial demonstrating anti-ageing or wellness efficacy.
Regulatory statusNo broad FDA/EMA anti-ageing or wellness indication for IV NAD+ identified.
Main limitationsDurable anti-ageing, energy, cognition, disease-prevention or lifespan benefit from IV NAD+.
SafetyIV administration can produce infusion-related symptoms; long-term clinical benefit/risk is inadequately characterized.
i
Direct IV NAD+ human evidence remains sparse. Small infusion studies characterize metabolism/tolerability, while a 2026 systematic review found no eligible IV/IM NAD+ outcome trial demonstrating anti-ageing or wellness efficacy.

What the evidence actually supports

  • ✓This is direct human infusion evidence but not proof of wellness benefit.
  • ✓Strong candidate for a 'mechanism vs clinical evidence' explainer.
  • ✓Use as a tolerability/safety record, not an efficacy claim.
  • ✓Prominent mechanism-versus-clinical-evidence distinction.

What is not established / key limitations

  • ×No evidence from this study that IV NAD+ improves energy, cognition or ageing outcomes.
  • ×No validated durable anti-ageing or cognitive outcome established for IV NAD+.
  • ×No evidence from this study of durable anti-ageing, cognitive or energy benefit.
  • ×Absence of eligible direct outcome trials is the key finding.

Selected study & evidence records

Six-hour intravenous NAD+ metabolome pilot

2019 · Pilot controlled human infusion study · n=11

The study characterized metabolism/excretion during infusion; it was not designed to establish anti-ageing, energy or cognitive efficacy.

Study detail → Primary source ↗

Intravenous infusion of NAD+ versus nicotinamide riboside: retrospective tolerability pilot

2026 · Retrospective real-world comparative pilot · n=Not stated here

IV NAD+ produced more infusion symptoms and substantially longer infusion times; exploratory metabolic changes were variable.

Study detail → Primary source ↗

NAD+ supplementation for anti-aging and wellness: PRISMA-guided systematic review

2026 · Systematic review · n=113 studies (33 human; 80 rodent)

Oral NR/NMN usually showed biochemical target engagement, but clinically meaningful outcomes were heterogeneous; no eligible IV/IM NAD+ outcome trial for anti-ageing/wellness was identified.

Study detail → Primary source ↗

Safety and unknowns

IV administration can produce infusion-related symptoms; long-term clinical benefit/risk is inadequately characterized.

Limited IV data report infusion-related symptoms including GI effects, increased heart rate and chest pressure; long-term benefit-risk is not adequately characterized.

Technical details

Mechanism / biologyCentral redox coenzyme in energy metabolism and substrate for enzymes including sirtuins/PARPs.
Route / formulation boundaryDo not conflate evidence for NAD precursors (NR/NMN) with IV NAD+ itself.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. Published human IV pilot regimen. See dosing_evidence records for route, regimen, population, duration and source.
Identifiers & alternate namesNAD · Nicotinamide adenine dinucleotide

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.